Payment overview · 2025
General Payments
$704.52
27 reported records · 11 companies
Healthcare provider profile · identity verified
Michael G Neret, MD
Allopathic & Osteopathic Physicians|Family Medicine · BAY CITY, TX · NPI 1306827951
Verified facts
What the public records show
CMS Open Payments records show Michael G Neret, MD received $704.52 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $270.02 | 38.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $130.13 | 18.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.02 | 12.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.00 | 5.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.05 | 5.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.22 | 4.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $26.79 | 3.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.03 | 3.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.44 | 3.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.92 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.90 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $704.52 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $213.73 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $199.85 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $198.16 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.02 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $88.95 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.92 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.99 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $48.70 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.05 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 217 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 27 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 28 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1235 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 367 | 126 |
| Gabapentin | Gabapentin | 273 | 75 |
| Pregabalin | Pregabalin | 272 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 263 | 86 |
| Alprazolam | Alprazolam | 232 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 65 |
| Potassium Chloride | Potassium Chloride | 226 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 225 | 68 |
| Furosemide | Furosemide | 219 | 61 |
| Eliquis | Apixaban | 217 | 38 |
| Memantine Hcl | Memantine Hcl | 205 | 54 |
| Ozempic | Semaglutide | 199 | 46 |
| Carvedilol | Carvedilol | 197 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 65 |
| Famotidine | Famotidine | 171 | 49 |
| Metformin Hcl | Metformin Hcl | 163 | 54 |
| Lisinopril | Lisinopril | 150 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 36 |
| Trazodone Hcl | Trazodone Hcl | 138 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 44 |
| Tramadol Hcl | Tramadol Hcl | 118 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 37 |
| Allopurinol | Allopurinol | 113 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 35 |
| Omeprazole | Omeprazole | 106 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 17 |
| Sertraline Hcl | Sertraline Hcl | 100 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 99 | 26 |
| Montelukast Sodium | Montelukast Sodium | 96 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 96 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 33 |
| Simvastatin | Simvastatin | 94 | 26 |
| Farxiga | Dapagliflozin Propanediol | 87 | 28 |
| Prednisone | Prednisone | 83 | 53 |
| Jardiance | Empagliflozin | 81 | 17 |
| Clonazepam | Clonazepam | 80 | 13 |
| Losartan Potassium | Losartan Potassium | 80 | 33 |
| Topiramate | Topiramate | 73 | 19 |
| Clonidine Hcl | Clonidine Hcl | 72 | 23 |
| Doxepin Hcl | Doxepin Hcl | 72 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 21 |
| Linzess | Linaclotide | 70 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 65 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 64 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 22 |
| Finasteride | Finasteride | 58 | 16 |
| Baclofen | Baclofen | 56 | 11 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Nifedipine Er | Nifedipine | 53 | 14 |
| Ondansetron Odt | Ondansetron | 53 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 19 |
| Fenofibrate | Fenofibrate | 50 | 20 |
| Diazepam | Diazepam | 49 | suppressed |
| Lorazepam | Lorazepam | 49 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 19 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Colchicine | Colchicine | 43 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 13 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Meloxicam | Meloxicam | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Metolazone | Metolazone | 29 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Nystatin | Nystatin | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Aristada | Aripiprazole Lauroxil | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $704.52 · 27 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, Veozah, XYOSTED, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error